Needham Initiates Coverage On Evommune with Buy Rating, Announces Price Target of $28

Benzinga Newsdesk www.benzinga.com Neutral 58.5%

Neg 0% Neu 58.5% Pos 0%

Needham analyst Serge Belanger initiates coverage on Evommune (NYSE:EVMN) with a Buy rating and announces Price Target of $28.